Antiplatelet and anticoagulant therapy in patients with giant cell arteritis

Michael S. Lee, Scott D. Smith, Anat Galor, Gary S. Hoffman

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Objective. Vision loss and cerebrovascular accidents often complicate giant cell arteritis (GCA). Antiplatelet and anticoagulant therapy reduce the risk of stroke in other populations. We sought to determine whether antiplatelet or anticoagulant therapy reduces ischemic complications in patients with GCA. Methods. A retrospective chart review for patients with GCA was conducted. Included patients fulfilled modified 1990 American College of Rheumatology criteria for GCA. Collected information included demographic data, dates of antiplatelet or anticoagulant use, vision loss or stroke, and presence of bleeding complications and cerebrovascular risk factors. Results. A total of 143 patients were included with a mean followup period of 4 years. The cohort included 109 women (76%) and 34 men (24%) with a mean age of 71.8 years. A total of 104 patients (73%) had a biopsy-proven diagnosis. Eighty-six patients (60.1%) had received long-term antiplatelet or anticoagulant therapy, including 18 (12.6%) who did not start therapy until after an ischemic event had occurred. Antiplatelet agents or anticoagulants were not used in 57 patients (39.9%). Overall, 11 of 68 patients (16.2%) had an ischemic event while receiving antiplatelet or anticoagulant therapy, compared with 36 of 75 patients (48.0%) not receiving such therapy (P < 0.0005). Univariate analysis failed to show a statistical difference between groups in regard to cerebrovascular risk factors, age, sex, or biopsy-proven diagnosis. Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy. Conclusion. Antiplatelet or anticoagulant therapy may reduce the risk of ischemic events in patients with GCA. An increased risk of bleeding complications was not observed.

Original languageEnglish
Pages (from-to)3306-3309
Number of pages4
JournalArthritis and Rheumatism
Volume54
Issue number10
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Giant Cell Arteritis
Anticoagulants
Therapeutics
Stroke
Hemorrhage
Biopsy
Platelet Aggregation Inhibitors
Warfarin
Aspirin

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. / Lee, Michael S.; Smith, Scott D.; Galor, Anat; Hoffman, Gary S.

In: Arthritis and Rheumatism, Vol. 54, No. 10, 01.10.2006, p. 3306-3309.

Research output: Contribution to journalArticle

Lee, Michael S. ; Smith, Scott D. ; Galor, Anat ; Hoffman, Gary S. / Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. In: Arthritis and Rheumatism. 2006 ; Vol. 54, No. 10. pp. 3306-3309.
@article{496b5a0e23f1420bb8cafe4dc77ab267,
title = "Antiplatelet and anticoagulant therapy in patients with giant cell arteritis",
abstract = "Objective. Vision loss and cerebrovascular accidents often complicate giant cell arteritis (GCA). Antiplatelet and anticoagulant therapy reduce the risk of stroke in other populations. We sought to determine whether antiplatelet or anticoagulant therapy reduces ischemic complications in patients with GCA. Methods. A retrospective chart review for patients with GCA was conducted. Included patients fulfilled modified 1990 American College of Rheumatology criteria for GCA. Collected information included demographic data, dates of antiplatelet or anticoagulant use, vision loss or stroke, and presence of bleeding complications and cerebrovascular risk factors. Results. A total of 143 patients were included with a mean followup period of 4 years. The cohort included 109 women (76{\%}) and 34 men (24{\%}) with a mean age of 71.8 years. A total of 104 patients (73{\%}) had a biopsy-proven diagnosis. Eighty-six patients (60.1{\%}) had received long-term antiplatelet or anticoagulant therapy, including 18 (12.6{\%}) who did not start therapy until after an ischemic event had occurred. Antiplatelet agents or anticoagulants were not used in 57 patients (39.9{\%}). Overall, 11 of 68 patients (16.2{\%}) had an ischemic event while receiving antiplatelet or anticoagulant therapy, compared with 36 of 75 patients (48.0{\%}) not receiving such therapy (P < 0.0005). Univariate analysis failed to show a statistical difference between groups in regard to cerebrovascular risk factors, age, sex, or biopsy-proven diagnosis. Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy. Conclusion. Antiplatelet or anticoagulant therapy may reduce the risk of ischemic events in patients with GCA. An increased risk of bleeding complications was not observed.",
author = "Lee, {Michael S.} and Smith, {Scott D.} and Anat Galor and Hoffman, {Gary S.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1002/art.22141",
language = "English",
volume = "54",
pages = "3306--3309",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Antiplatelet and anticoagulant therapy in patients with giant cell arteritis

AU - Lee, Michael S.

AU - Smith, Scott D.

AU - Galor, Anat

AU - Hoffman, Gary S.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Objective. Vision loss and cerebrovascular accidents often complicate giant cell arteritis (GCA). Antiplatelet and anticoagulant therapy reduce the risk of stroke in other populations. We sought to determine whether antiplatelet or anticoagulant therapy reduces ischemic complications in patients with GCA. Methods. A retrospective chart review for patients with GCA was conducted. Included patients fulfilled modified 1990 American College of Rheumatology criteria for GCA. Collected information included demographic data, dates of antiplatelet or anticoagulant use, vision loss or stroke, and presence of bleeding complications and cerebrovascular risk factors. Results. A total of 143 patients were included with a mean followup period of 4 years. The cohort included 109 women (76%) and 34 men (24%) with a mean age of 71.8 years. A total of 104 patients (73%) had a biopsy-proven diagnosis. Eighty-six patients (60.1%) had received long-term antiplatelet or anticoagulant therapy, including 18 (12.6%) who did not start therapy until after an ischemic event had occurred. Antiplatelet agents or anticoagulants were not used in 57 patients (39.9%). Overall, 11 of 68 patients (16.2%) had an ischemic event while receiving antiplatelet or anticoagulant therapy, compared with 36 of 75 patients (48.0%) not receiving such therapy (P < 0.0005). Univariate analysis failed to show a statistical difference between groups in regard to cerebrovascular risk factors, age, sex, or biopsy-proven diagnosis. Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy. Conclusion. Antiplatelet or anticoagulant therapy may reduce the risk of ischemic events in patients with GCA. An increased risk of bleeding complications was not observed.

AB - Objective. Vision loss and cerebrovascular accidents often complicate giant cell arteritis (GCA). Antiplatelet and anticoagulant therapy reduce the risk of stroke in other populations. We sought to determine whether antiplatelet or anticoagulant therapy reduces ischemic complications in patients with GCA. Methods. A retrospective chart review for patients with GCA was conducted. Included patients fulfilled modified 1990 American College of Rheumatology criteria for GCA. Collected information included demographic data, dates of antiplatelet or anticoagulant use, vision loss or stroke, and presence of bleeding complications and cerebrovascular risk factors. Results. A total of 143 patients were included with a mean followup period of 4 years. The cohort included 109 women (76%) and 34 men (24%) with a mean age of 71.8 years. A total of 104 patients (73%) had a biopsy-proven diagnosis. Eighty-six patients (60.1%) had received long-term antiplatelet or anticoagulant therapy, including 18 (12.6%) who did not start therapy until after an ischemic event had occurred. Antiplatelet agents or anticoagulants were not used in 57 patients (39.9%). Overall, 11 of 68 patients (16.2%) had an ischemic event while receiving antiplatelet or anticoagulant therapy, compared with 36 of 75 patients (48.0%) not receiving such therapy (P < 0.0005). Univariate analysis failed to show a statistical difference between groups in regard to cerebrovascular risk factors, age, sex, or biopsy-proven diagnosis. Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy. Conclusion. Antiplatelet or anticoagulant therapy may reduce the risk of ischemic events in patients with GCA. An increased risk of bleeding complications was not observed.

UR - http://www.scopus.com/inward/record.url?scp=33750337784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750337784&partnerID=8YFLogxK

U2 - 10.1002/art.22141

DO - 10.1002/art.22141

M3 - Article

C2 - 17009265

AN - SCOPUS:33750337784

VL - 54

SP - 3306

EP - 3309

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -